Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Stemline Therapeutics, Inc.
Advances in™: Diagnosis and Treatment of BPDCN Around the World!
Release Date: December 23, 2021
Expiration Date: December 23, 2022
Activity Overview
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Stemline Therapeutics, Inc.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Discuss diagnostic challenges in the context of evolving strategies to facilitate early BPDCN identification
- Describe clinical and laboratory approaches for the differential diagnosis of BPDCN
- Assess the rationale for targeting CD123 in BPDCN and recent efficacy and safety findings from clinical trials conducted in treatment-naïve and relapsed forms of disease
- Determine practical methods to integrate recent evidence on therapies targeting CD123 into clinical practice in the management of BPDCN
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
Faculty
Associate Professor
Director, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Program
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant/Research support: Affymetrix, SagerStrong Foundation. Consultant: Pacylex Pharmaceuticals; ImmunoGen; Bristol Myers Squibb; Blueprint Medicines; Clearview Healthcare Partners; Astellas Pharma US, Inc.; Protagonist Therapeutics, Inc.; Triptych Health Partners; CTI Biopharma. Speaker’s bureau: Incyte; Novartis; LFB Biotechnologies; Stemline Therapeutics, Inc.; Celgene; AbbVie; Mustang Bio, Inc.; Roche Diagnostics; Blueprint Medicines; DAVA Oncology; Springer Science+Business Media LLC; Aptitude Health; NeoPharm Israel; CareDx, Inc. Other support: Novartis; Stemline Therapeutics, Inc.; Samus Therapeutics, Inc.; AbbVie; Cellectis; Affymetrix; Daiichi Sankyo; Plexxikon; Mustang Bio, Inc. (research support).
Professor
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Grant/Research support: ImmunoGen; Consultant: Stemline Therapeutics, Inc.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
